Key Highlights

  • Eli Lilly rose 3.36% to USD 1,205.66 on October 14, leading the S&P 500, while Merck gained about 3.8% and AbbVie closed up 3.03% at a record USD 282.66.
  • A hotter-than-expected September CPI report revived bets on Fed rate hikes, lifted the 10-year Treasury yield to about 5.28% and sent the Nasdaq Composite down 1.88% as investors sold AI stocks.
  • No major company news drove the three stocks, so the moves reflect a rotation into defensive healthcare, with Lilly at about 31 times forward earnings against a three-year average near 40 times.
  • Third-quarter results are next, with AbbVie due October 30 after trimming its quarterly EPS guidance for acquired research costs, and the Fed meets again on October 27 and 28.

What Drove the Healthcare Rally

Large pharmaceutical stocks led the market on October 14 while the major indexes fell. Eli Lilly gained 3.36%, or USD 39.14, to close at USD 1,205.66 and was the S&P 500's top performer. Merck rose about 3.8% and AbbVie gained about 3.0% to 3.3%, closing at USD 282.66 a record close and within about 1% of its USD 285.40 intraday peak, simple arithmetic. The trigger was macro, not company-specific. September CPI came in hotter than expected, which revived expectations that the Fed could raise rates again at its October 27 and 28 meeting. The 10-year Treasury yield rose to about 5.28% and the 30-year to about 5.59%, and the Nasdaq Composite fell 1.88% while the VIX rose 10.48%. Investors sold AI-linked and speculative stocks and moved into sectors whose earnings depend less on cheap credit. No major Lilly, Merck or AbbVie announcement explained the gains, and AbbVie saw 86,296 call options traded, about 445% above typical volume, which suggests traders were positioning for further upside.

Why Lilly, Merck and AbbVie Led

Eli Lilly is an unusual defensive pick because it is a growth stock, but its earnings run on obesity drug demand and not on AI spending. Mounjaro and Zepbound generated USD 12.8 billion in the first quarter, and analysts expect normalized EPS to climb from USD 24.21 in 2025 to USD 35.22 in 2026, up 45%, and USD 47.48 in 2027. That growth has pulled the multiple down: Lilly trades near 31 times forward earnings, below its three-year average near 40 times and a 67 times peak.AbbVie is up about 24% this year, with a market value near USD 501 billion and a 52-week range of USD 190.75 to USD 285.40. Skyrizi is projected to reach about USD 21.7 billion in annual sales, and AbbVie trades near 16 times forward earnings, well below Lilly. On October 6 it lowered third-quarter adjusted EPS guidance to USD 3.73 to USD 3.77 from USD 3.84 to USD 3.88 after USD 216 million of acquired research costs. Merck faces a patent cliff of its own: Keytruda sales of USD 7.904 billion declined 1% in the latest reported quarter, and Merck trades at a discount to AbbVie, which fits its slower growth. Its 3.8% gain reflects sector flows more than a new catalyst.

Risks and What to Watch

The rally rests on rotation, which can reverse quickly if inflation cools or AI sentiment recovers. Drug pricing and tariff headlines remain a standing sector risk, and Lilly's earnings are concentrated in obesity drugs. AbbVie sits within about 1% of its 52-week high, so a quarterly miss or a further guidance change could be punished, and Merck still has to replace Keytruda revenue as patents expire. What to watch next: the Fed meeting on October 27 and 28, AbbVie's results on October 30 and the third-quarter reports from Lilly and Merck, which should show whether earnings growth can support current multiples. This is information only and not investment advice.

Where Things Stand

Healthcare held up on October 14 because investors wanted earnings that do not depend on AI spending or easy credit, and Lilly, Merck and AbbVie were the largest beneficiaries. The moves came without company news, so they depend on the inflation and rate backdrop as much as on fundamentals. Lilly offers faster earnings growth at a lower multiple than its history, AbbVie offers momentum near a record, and Merck offers a discount with patent risk. A one-day rotation can fade, so the balance of evidence favors waiting for the next catalysts. Direction remains unknown, and the next catalyst is AbbVie's October 30 report.